LLL 3348

Drug Profile

LLL 3348

Alternative Names: Desoris; Herbal anti-psoriasis compound LLL-3348 (Desoris) - Lupin Ltd; LL 3348; LLL-3348

Latest Information Update: 18 Jun 2015

Price : $50

At a glance

  • Originator Lupin
  • Class Antipsoriatics
  • Mechanism of Action Cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Plaque psoriasis

Most Recent Events

  • 18 Jun 2015 No recent reports on development identified - Phase-II/III for Plaque psoriasis in India (PO)
  • 11 Dec 2013 Lupin completes a phase II/III trial in Plaque psoriasis in India
  • 05 Apr 2011 Lupin completes enrolment in its phase IIb/III trial for Plaque psoriasis in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top